Navigation Links
May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO
Date:5/14/2009

Data support proteomic test as a predictor of overall survival benefit with EGFRI treatment

BROOMFIELD, Colo., May 14 /PRNewswire/ -- Data on VeriStrat, a blood-based, proteomic test currently used for patients with advanced stage non-small-cell lung cancer (NSCLC), will be presented by Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University on Monday, June 1st at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a 314 patient study indicate that VeriStrat is predictive of survival benefit in patients with squamous cell carcinoma of the head and neck (SCCHN) treated with epidermal growth factor inhibitors (EGFRIs). According to the data, VeriStrat provides information to help oncologists identify patients most likely to benefit from EGFRI therapy.

In the study, VeriStrat was used to classify outcomes in patients with SCCHN who were treated with gefitinib (G), erlotinib and bevacizumab (E/B), cetuximab (C), or palliative chemotherapy (PC). Gefitinib, erlotinib and cetuximab are EGFRIs with activity in SCCHN. Results from the study show that among patients treated with EGFRIs, VeriStrat predicted an overall survival benefit (G: p=0.007, HR 0.41; E/B: p=0.02, HR 0.20; C: p=0.06, HR-0.26). VeriStrat did not classify survival outcomes in patients treated with palliative chemotherapy (PC: p=0.76, HR 0.88).

"At present, there are no validated diagnostic tests to guide therapy selection for patients with SCCHN. Having a blood test that provides results which will help oncologists decide whether or not to treat head and neck cancer patients with anti-EGFR agents would be a major advancement in the treatment of this disease," stated Ezra Cohen, MD, Associate Professor of Medicine at the University of Chicago and a study investigator.

The data support previous study results in which VeriStrat effectively identified patients with NSCLC who were likely to have good or poor outcomes following treatment with EGFRIs (J Natl Cancer Inst. 2007;99(11):838-46). Additional studies are underway to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other EGFRIs.

A study reporting results evaluating the association of VeriStrat status and genetic features with survival after treatment with erlotinib in patients with NSCLC will also be presented on Saturday, May 30th. For more information on the time and locations of these presentations, visit www.asco.org.

"The data to be presented at ASCO validate our molecular profiling approach to identify patient populations who are most likely to benefit from targeted therapies as well as those who are unlikely to receive any benefit," said Heinrich Roder, D.Phil., Chief Technical Officer at Biodesix. "Biodesix is committed to advancing personalized medicine as we continue our research in identifying the relationship between disease, mass spectrometry profiles and therapies. The data from ASCO, coupled with our previous research, show that VeriStrat is effective at predicting outcomes to therapeutics affecting the EGFR pathway, independent of their specific mode of action, and for tumor types where this is a targeted pathway. This brings us one step closer to a healthcare model that is highly personalized."

About VeriStrat: VeriStrat is a pretreatment serum, proteomic test for patients with advanced NSCLC. The test identifies patients who are likely to have good or poor outcomes after treatment with EGFRIs. Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat has been validated in clinical studies with over 1000 patients. Biodesix is engaging in additional studies to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other EGFRIs. For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.

About Biodesix: Biodesix is a fully integrated molecular diagnostic company enabling personalized medicine using mass spectrometry-based molecular profiling. Working with academic and biopharma collaborators, Biodesix uses its proprietary technology, ProTS(R), to discover and validate diagnostic tests that improve patient outcomes. Biodesix' first product, VeriStrat, is commercially available for physicians to help guide their treatment of patients with non-small cell lung cancer. For more information on Biodesix, visit www.Biodesix.com.

This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Biodesix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
2. ESA to Launch Corona(R) ultra(TM) at Pittcon 2009: Booth #1080
3. Hospital Build Asia Exhibition and Congress 2009: Regions Most Comprehensive Healthcare Infrastructure Planning and Development Event to Debut in Singapore
4. National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure
5. Lower Your Grocery Bill, Improve Health In 2009: Top Tips From Dr. Praegers Sensible Foods
6. Pharmacy Technician Certification Board (PTCB) Unveils New Testing Features for 2009: PTCB Exam to be Offered Daily; Test Results Given to Candidates Immediately in 2009
7. 2009: The Year of Health Care Reform? Faith-Based Investors See Doubling of Related Shareholder Resolutions, Growing Public Support From Corporate America
8. Nutrition Software nutrinote 2009: Lose Weight With the Help of a Computer
9. NewCardio to Present at OneMedForum 2009: Disrupters and Drivers on January 13 in San Francisco
10. OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions
11. SAGE launching new sports medicine journal in 2009: Sports Health: A Multidisciplinary Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... 21, 2017 , ... Hanna Boys Center http://www.hannacenter.org ... the keynote speaker at its second Professional Networking Breakfast on March 9, 2017. ... comprehensive strategies to create and expand opportunities for boys and young men of ...
(Date:2/21/2017)... ... February 21, 2017 , ... Ray Insurance Agencies, a Dallas ... around Tarrant County, is embarking on a six month charity event aimed at raising ... cancer. , Cancer is one of the deadliest diseases in America; more than 7.5 ...
(Date:2/21/2017)... ... February 21, 2017 , ... Each February ... History Month (officially African American History Month ). This month-long ... of a diverse race of people, but also the opportunity to examine the ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on ... loss. It found that the treatments have led to significant improvements in weight loss ... unassisted efforts. It also noted very few problematic results relating to the treatment. Beverly ...
(Date:2/20/2017)... OAK BROOK. Ill. (PRWEB) , ... February 20, 2017 , ... ... at high risk–according to a new study from Germany published online in the journal ... cancer screening modality that offers better sensitivity than mammography and ultrasound. Currently, guidelines reserve ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 2017 Diabetic Shoes Market: Overview Read ... ... a disease, which is marked by high levels of blood ... The disease has become a global epidemic leading to serious ... organs of the body including eyes, kidneys, heart. However, it ...
(Date:2/21/2017)... 21, 2017 Medical Oxygen Concentrators Market: ... http://www.reportlinker.com/p04711311-summary/view-report.html Medical oxygen concentrators are used ... diseases. Patients having low level of oxygen in ... Oxygen concentrators are to be used only with ... Medical oxygen concentrators work either on rechargeable lithium ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
Breaking Medicine Technology: